Prestige Biopharma eyes at least 1.8t won valuation in Korean IPO

Singapore

SINGAPORE-BASED Prestige Biopharma expects an implied market capitalisation of between 1.8 trillion won and 1.93 trillion won (S$2.2 billion to S$2.3 billion) in its upcoming initial public offering (IPO) on the Korea Exchange (KRX), the company told The Business Times.

As it looks to list early this year, the biotech firm also plans to expand its headcount from the current 70 to about 300 staff, possibly in the next five years, its chief executive Lisa Park told BT.